Streetbeat News

Earnings

TCRX

Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) vary from bullish to bearish, with a majority being bullish. The average 12-month price target is $12.43, reflecting a slight increase. Despite a significant decline in revenue, the company shows strong financial health in other metrics.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 3:01 pm

REGN

The article provides a comprehensive analysis of Regeneron Pharmaceuticals (NASDAQ:REGN) and its primary competitors in the Biotechnology industry. Key financial metrics, market position, and growth prospects are examined to offer valuable insights for investors. Regeneron shows potential undervaluation with low PE, PB, and PS ratios compared to peers, and strong profitability indicated by high ROE, EBITDA, and gross profit. However, its low revenue growth is a concern.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 3:00 pm

MRK

The article provides a comparative analysis of Merck & Co (NYSE:MRK) against its major competitors in the Pharmaceuticals industry. Key financial metrics such as P/E, P/B, P/S, ROE, EBITDA, gross profit, and revenue growth are evaluated. Merck & Co shows a high P/E ratio, indicating potential overvaluation, but low P/B and P/S ratios, suggesting undervaluation. The company lags behind its competitors in ROE, EBITDA, gross profit, and revenue growth, signaling weaker financial performance and growth prospects.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 3:00 pm

IPSC

Over the past three months, five analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), with ratings ranging from bullish to bearish. The average 12-month price target is $13.6, with a high of $24.00 and a low of $9.00. Recent financial performance shows a decline in revenue growth and challenges in profitability, but the company has a strong ROE and ROA, and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 3:00 pm

AAPL

HPE

NTAP

PSTG

SMCI

The article provides a detailed analysis of Apple Inc. (NASDAQ:AAPL) in comparison to its competitors in the Technology Hardware, Storage & Peripherals industry. Key financial metrics such as P/E, P/B, P/S ratios, ROE, EBITDA, and gross profit are examined, highlighting Apple's strong profitability but slower revenue growth.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 3:00 pm

HPE

Hewlett Packard Enterprise (NYSE:HPE) is expected to report lower Q2 earnings, with analysts forecasting 39 cents per share, down from 52 cents a year ago. Revenue is projected at $6.82 billion. Recent analyst ratings show mixed sentiments, with some raising and others lowering price targets.

Portfolio Pulse from Avi Kapoor

June 04, 2024 | 2:39 pm

HPE

Hewlett Packard Enterprise Co (NYSE:HPE) is set to report its Q2 earnings on June 4, with Wall Street expecting 39 cents in EPS and $6.83 billion in revenues. The stock has shown a 19.51% increase over the past year and 5.71% year-to-date. HPE is benefiting from the rising demand for AI and is diversifying through investments in networking capabilities, including the acquisition of Juniper Networks and the launch of HPE Aruba Networking Enterprise Private 5G. Despite economic concerns, technical analysis indicates a bullish trend for HPE stock in the near term.

Portfolio Pulse from Surbhi Jain

June 04, 2024 | 2:36 pm

AMZN

COST

TGT

UBER

WBA

WMT

Costco Wholesale Corporation (NASDAQ:COST) reported strong fiscal third quarter earnings, with revenue growing 9% YoY to $58.52 billion and e-commerce sales surging 20.7%. The company emphasized its value proposition, digital sales growth, and expanded partnership with Uber Technologies Inc (NYSE:UBER). Costco's strategy of lowering prices has helped it gain market share in a challenging retail environment. The company is also expanding its store footprint and has delayed raising membership prices to retain its growing member base.

Portfolio Pulse from Upwallstreet

June 04, 2024 | 2:32 pm

Whales have taken a bearish stance on Micron Technology (NASDAQ:MU), with 59% of recent options trades being bearish. The stock is currently trading at $125.78, down by 1.86%. Analysts have mixed ratings, with a consensus target price of $146.0.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 2:31 pm

VKTX

Viking Therapeutics Inc (NASDAQ:VKTX) released 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with non-alcoholic steatohepatitis (NASH). The study achieved its primary and secondary endpoints, showing significant improvements in liver fat content, NASH resolution, and fibrosis improvement. VKTX shares are up 5.19% in premarket trading.

Portfolio Pulse from Vandana Singh

June 04, 2024 | 2:29 pm